Strides Pharma Reports Strong PBT Growth Amid Declining Profit After Tax in June 2025

Strides Pharma Science, a midcap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending June 2025. The evaluation changes reflect a notable shift in the company's score, which has adjusted to 7 from 28 over the past three months.
The financial data reveals several positive trends for Strides Pharma. The Profit Before Tax less Other Income (PBT) reached Rs 121.83 crore, showcasing a significant year-on-year growth of 103.91%. This marks the highest PBT recorded in the last five quarters, indicating a strong near-term trend. Additionally, the company's Operating Profit to Interest ratio has improved, now standing at 4.60 times, suggesting enhanced management of interest payments.

On the balance sheet front, Strides Pharma has achieved a Debt-Equity Ratio of 0.74 times, the lowest in the last five half-yearly periods, reflecting a reduction in borrowing relative to equity capital. The Operating Cash Flow has also reached its peak at Rs 421.48 crore over the past three years, indicating robust cash generation from operations.

However, the financial results also highlight challenges, particularly with the Profit After Tax (PAT), which has seen a year-on-year decline of 74.0%, indicating a negative near-term trend.

For more insights on Strides Pharma's financial performance and evaluation changes, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.